Peter joined Nan Fung Life Sciences in 2017. Before joining us, Mr. Peter Bisgaard was a senior partner at Novo Ventures and has been with Novo Ventures (US) Inc. since 2009. As part of Novo’s senior team he was responsible for Novo Venture’s overall investment and portfolio strategy as well as ongoing development of Novo Ventures team in the US. Prior to that, he was with Novo A/S since 2001 in Denmark. He has investment and board experience from a large number of private and public US life sciences companies. Prior to joining Novo A/S, Peter was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. He was part of strategic and financial advisor team in multiple large Private Equity and Corporate M&A transactions and strategy projects across industry sectors.
Mr. Peter Bisgaard obtained an MSs in Engineering in 1998 from the Technical University of Denmark and was awarded a post graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.
Meng joined Nan Fung Life Sciences in 2015. Prior to joining us, Meng was a Managing Director at Blackstone’s Private Equity Group in Hong Kong. At Blackstone, he was involved in a number of transactions across multiple industries. Before joining Blackstone, Meng was a Senior Vice President at Oaktree Capital Management, where he was involved in sourcing, structuring and executing private equity investments in China. Prior to that, Mr. Gao was an investment banker with Credit Suisse and JPMorgan in New York.
Meng received a Bachelor of Economics degree from Peking University, an M.A. from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honours.
Meng joined Nan Fung Life Sciences in 2017. Prior to joining us, Meng was a Senior Associate at AlpInvest, a wholly owned subsidiary of the Carlyle Group which focuses on global fund of funds investments. At AlpInvest, he was the key person in managing the firm’s primary fund investments portfolio in Greater China. Before joining AlpInvest, Meng was an Associate at Oaktree Capital Management, where he was part of the Asia Principal Investment Team. Meng was involved in sourcing, executing and monitoring various Oaktree’s private equity investments in Asia Pacific. Prior to Oaktree, Meng was an M&A investment banker at Credit Suisse in New York and Hong Kong.
Meng received a Bachelor of Science degree in Biomedical Engineering from Columbia University, and a Master of Science in Operations Research, also from Columbia.
Prior to joining Nan Fung Life Sciences, Davis gained 7 years of experience working with BVCF, the first fund in China focused on PE/VC investments in the country’s life sciences and healthcare industries. There, he led deals with a focus on cross-border strategies in antibacterial, hormone replacement, and OBGYN companies and served as Board Director or observer in each. In addition, he helped develop and execute BVCF’s fundraising and investor relations program leading to successfully closing BVCF’s third fund. Before that, he served with Memorial Sloan-Kettering Cancer Center’s Department of Strategic Planning and Innovation, where he helped develop strategies for optimizing operations and for larger scale institutional and business growth.
Davis earned his MBA at the University of Chicago Booth School of Business, and his Bachelor of Arts degree at Yale University.
Jeni joined Nan Fung Life Sciences in 2019. She previously spent 3 years at Novo Ventures, supporting the firm’s investments in private and public life sciences companies across the therapeutics, medical device, diagnostics, and digital health sectors. While at Novo, she served as a Board Observer at Inozyme Pharma. Prior to Novo, Jeni supported the Director of Research at Aquilo Capital Management, a hedge fund focused on smid cap biotechs. Additionally, Jeni was a co-founder of ViVita Technologies, a cardiovascular-focused preclinical medtech startup. Jeni volunteers with the New England Venture Network (NEVN), a young professionals organization for aspiring venture capitalists, as well as the Breaking 7% network to promote women in venture capital.
Jeni earned her Ph.D. in Biomedical Engineering with a Designated Emphasis in Biotechnology from the University of California, Davis, and her B.S. from the University of California, Berkeley.